Specific antioxidant properties of human serum albumin.
PDF (326K)
Journal: 2013/February - Annals of Intensive Care
ISSN: 2110-5820
Abstract:
Human serum albumin (HSA) has been used for a long time as a resuscitation fluid in critically ill patients. It is known to exert several important physiological and pharmacological functions. Among them, the antioxidant properties seem to be of paramount importance as they may be implied in the potential beneficial effects that have been observed in the critical care and hepatological settings. The specific antioxidant functions of the protein are closely related to its structure. Indeed, they are due to its multiple ligand-binding capacities and free radical-trapping properties. The HSA molecule can undergo various structural changes modifying its conformation and hence its binding properties and redox state. Such chemical modifications can occur during bioprocesses and storage conditions of the commercial HSA solutions, resulting in heterogeneous solutions for infusion. In this review, we explore the mechanisms that are responsible for the specific antioxidant properties of HSA in its native form, chemically modified forms, and commercial formulations. To conclude, we discuss the implication of this recent literature for future clinical trials using albumin as a drug and for elucidating the effects of HSA infusion in critically ill patients.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(56)
References
(65)
Drugs
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Annals of Intensive Care. Dec/31/2012; 3: 4-4
Published online Feb/14/2013
PMID: 23414610
PMC: 3577569

Specific antioxidant properties of human serum albumin

Abstract

Review

Introduction

Clinically, Human Serum Albumin (HSA) is used for the restoration of blood volume, emergency treatment of shock, acute management of burns, and other situations associated with hypovolemia [1]. Many studies have focused on the use of albumin as a resuscitation fluid and its effects on patient outcomes in Intensive Care Units (ICU). Some of them have revealed that use of either albumin or normal saline for resuscitation fluid results in similar outcomes [2]. Others have shown negative impacts: for example, in a prospective cohort study, hyperoncotic albumin infusion was associated with harmful effects on renal function and outcome [3]. Conversely, other studies have demonstrated positive effects or beneficial trends of albumin infusion [4]. In a large controlled, randomized trial, the administration of albumin may have decreased the risk of death in patients with severe sepsis compared with saline [5]. Furthermore, a randomized, controlled trial in patients with cirrhosis and spontaneous bacterial peritonitis has shown that the addition of an albumin infusion to an antibiotic treatment significantly reduced the incidence of renal impairment and death [6]. The several meta-analyses assessing the effectiveness of albumin solutions for resuscitation in critically i1l patients failed to clarify this issue [7-10]. In this context, the choice of a resuscitation fluid in ICU patients is still a conflicting matter under debate, and it is not the scope of the present review to provide an answer to this issue. Our objective is rather to highlight the mechanisms by which albumin might exert its potential beneficial effects in the critical care and hepatological settings.

Among the hypotheses that have been proposed to explain the positive effects of albumin, its antioxidant properties seem to be of paramount importance [11-14]. This hypothesis is supported by the central role of oxidative stress in critical pathologies, such as sepsis or liver failure [1,15]. Indeed, the pathophysiology of sepsis may be characterized by the negative role of free radicals during the onset, progression, and outcome of sepsis [16,17]. Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) exert their detrimental effects at least partially, through endothelial dysfunction with alterations of vascular tone, increased cell adhesion, and vascular permeability [18,19]. The activation of endothelial cells contributes to maintain the oxidant-rich environment at the inflammatory locus [20]. Moreover, high levels of ROS and RNS can result in organ damages [21], the ROS amount being related to the severity of sepsis and mortality [20]. In the same way, oxidative stress is very high in cirrhotic patients and plays an important role in the pathophysiological mechanisms involved in the hemodynamic disturbances observed [16,22]. Indeed, excessive systemic Nitric Oxide (NO) production is involved in peripheral vasoplegia, which induces portal hypertension, an important complication of cirrhosis [23]. The detrimental role of oxidative stress occurs during both the onset of hepatic alterations and during progression stages of the disease, in correlation with the severity of cirrhosis [24].

The detrimental role of oxidative damage in critical pathologies, added to the demonstration of potential positive effects of albumin infusion in these patients, constitute a strong rationale that justifies for addressing the specific antioxidant capacities of HSA [11-14]. Our review summarizes the state of the art on this topic and focuses on the antioxidant properties of HSA related to (i) first its native form, (ii) the chemically modified-HSA (iii) the commercial HSA. The implication of this recent literature for future clinical trials using albumin as a drug is finally discussed.

Specific antioxidant capacities of native HSA

Albumin is a non-glycosylated protein of 66 kDa [25,26]; its normal plasma concentration is between 35 and 50 g/l constituting up to 60% of total plasma proteins [27]. Its half-life is ~ 20 days in normal conditions. The HSA structure consists of a single-chain polypeptide of 585 amino acid residues and approximately 67% alpha-helix and no beta-sheet [28,29]. Native HSA contains 6 methionines and 35 cysteine residues involved in the formation of 17 disulfide bonds. The Cys-34 residue is the only free cysteine in the whole molecule. HSA exerts specific antioxidant functions due to its multiple ligand-binding capacities and free radical-trapping properties, both closely related to its structure [16,29].

HSA antioxidant properties related to ligand-binding capacities

HSA is well known for binding a large variety of molecules, including fatty acids, drugs, hormones, and metal ions [27]. The main ligands of HSA implied in direct or indirect antioxidant functions of the protein are transition metal ions (copper and iron essentially) [15]. The high affinity site for Cu(II) ions is composed of the first four amino acids Asp-Ala-His-Lys (DAHK) from the N-terminus of HSA [30,31]. Free redox-active transition metal ions (Cu(II) and Fe(II)) can potentially be extremely pro-oxidant. Indeed, through the Fenton reaction, they can interact with hydrogen peroxide (H2O2) catalyzing the formation of aggressive ROS. The net result of the reaction sequence is known as the Haber-Weiss reaction, showing that iron and copper are the most important transition metals in human disease and play a key role in the production of hydroxyl radicals in vivo[30,32]. The binding of free transition metals to proteins can control their reactivity and limit their availability for the Fenton reaction [30,32]. HSA might then be able to limit damage caused by hydroxyl radicals produced from Fenton reaction between iron/copper and H2O2[31].

Other aspects of the antioxidant activity of albumin result from to its ability to bind bilirubin, homocysteine, and lipids but are of minor importance compared with metal ion involvement in HSA antioxidant properties. HSA contains one high affinity site (Lys240) for bilirubin [33]. The resulting HSA-bound bilirubin acts as an inhibitor of lipid peroxidation and thus represents an indirect antioxidant property of HSA [34]. Another aspect of HSA antioxidant properties is its capacity to bind homocysteine, a sulfur-containing amino acid resulting from the catabolism of methionine residue [35]. Some previous studies have suggested that the binding of HSA to polyunsaturated fatty acids and sterols could contribute to its antioxidant properties, by preventing lipid peroxidation. Additional studies are necessary to document this HSA protective capacity [36,37].

HSA antioxidant properties related to free radical-trapping properties

Upon secretion in physiological conditions, one-third of the HSA pool exists as disulfides mixed with cysteine, homocysteine, or glutathione (GSH) (HSA-S-S-R) and two-thirds of the HSA molecules exist in a reduced form with a free thiol in the Cys-34 residue (HSA-SH), known as human mercaptalbumin [37,38]. This redox thiol group, in connection with the high concentration of HSA in the circulation, accounts for 80% thiols in plasma, constituting the major extracellular source of reactive free thiol [16,25,39]. Working as a free radical scavenger, the Cys34 residue is able to trap multiple ROS and RNS, such as hydrogen peroxide (H2O2), peroxynitrite (ONOO-), superoxide, or hypochlorous acid (HOCl) [15,16,40]. Under oxidative stress by peroxynitrite or hydrogen peroxide, Cys34 thiol shifts to an exposed conformation and is oxidized itself resulting in sulfenic acid (HSA-SOH) formation. HSA-SOH is a central intermediate in the redox modulation by reactive species. The final outcome of the oxidative process depends on whether the sulfenic acid is further oxidized, or whether it is reduced leading to the initial HSA-SH. Sulfenic acid may be oxidized to either sulfinic (HSA-SO2H) or sulfonic (HSA-SO3H) acids, by usually irreversible processes leading to end products [41,42]. Sulfenic acid also can be converted into a disulfide (HSA-S-S-R), through reactions with low-molecular-mass-thiol (RSH, glutathione or free cysteine) allowing the return to the HSA-SH reduced form [37,43]. This HSA implication in disulfides formation supports a relevant function of HSA-SH as an extracellular redox regulator (Figure 1) [42]. HSA also could protect cells against oxidative stress by modulating the cellular GSH level. Indeed, catabolism of HSA could potentially represent a source of sulfur-containing amino acids for cells in the synthesis of thiol-containing molecules, such as GSH [44].

Figure 1

Scheme gives an overview of the steps leading to Cys-34 oxidation and thiolation (highlighted in red). Steps involved for the nitrosylation of Cys-34 of human serum albumin (HSA) are highlighted in green. Formation of higher oxidation states of HSA is also shown. RSH, glutathione or free cysteine.

Under nitrosative stress by NO or other nitrosylating agents, mercaptalbumin can be converted into nitroso-HSA (HSA-S-NO) [37]. HSA-S-NO can transfer the nitrosonium cation to low-molecular-mass-thiol RSH (glutathione or free cysteine). The HSA-mediated catalysis of RSH allows the return to the HSA-SH form and makes the protein a major reservoir of NO (Figure 1) [37,45].

As cysteine amino acid, methionine also is a sulfur-containing residue, representing an oxidation-sensitive amino acid [46,47]. HSA contains six methionines residues that can be oxidized, leading to methionine sulfoxide [48].

The two sulfur-containing residues in HSA, Met and Cys, have then been proved to account for 40-80% of the total antioxidant activity of the protein, which is responsible for more than 70% of the free radical-trapping activity in serum [28,46,47]. In conclusion, HSA is considered as the main extracellular molecule responsible for maintaining the plasma redox state [11,37,49].

Impairments of specific antioxidant capacities of HSA

The various structural modifications that HSA can undergo during its in vivo lifetime or during the processes employed to isolate therapeutic HSA from plasma, modify not only its conformation and hence its binding properties but also its redox state [16,50,51]. Kawakami et al. have clearly shown that reduced HSA and oxidized HSA have different ligand-binding properties [50]. These authors also have investigated the potential effect of oxidation on the antioxidant capacity of HSA by comparing the radical scavenging activities of HSA in various states of oxidation [50]. By using electron spin resonance, they have observed that the hydroxyl radical signal is reduced from 68.7% with highly oxidized cysteinylated HSA (proportion of HSA reduced = 8%) to 54.4% with non-oxidized HSA (proportion of HSA reduced = 73%). They have then demonstrated that the radical scavenging activity of reduced HSA is greater than that of cysteinylated HSA [50]. Those results are in accordance with other reports establishing that oxidized HSA decreases scavenging ability against highly ROS (hydroxyl radicals). Similarly, HSA nitrosylation leads to a significant loss of its buffering capacity [52]. Moreover, the loss of aspartate-alanine from the N-terminus of albumin completely abolishes the ability of albumin to chelate free copper and is associated with the loss of its free radical scavenging ability [52]. Finally, Iwao et al. (2006) demonstrated that oxidation of several amino acids of albumin had an impact on its pharmacokinetics by decreasing its half-life [53].

Beyond oxidation and nitrosylation, HSA may undergo other chemical modifications affecting its structure, which is closely related to its specific antioxidant properties [27]. One of them is a non-enzymatic glycation consisting in the attachment of free carbohydrate (glucose, galactose, fructose…) on an amine residue leading to the formation of a stable fructosamine residue [54]. Accumulation of numerous studies has permitted to identify up to 29 sites that can be glycated in vivo in the HSA [34]. Due to their high nucleophile properties, lysine, arginine and cysteine are the main residues prone to glycation and the two principal sites are Arg410 and Lys525 [55,56]. Glycation-induced modifications have an important impact on HSA functional properties mainly related to alteration of its conformation. These conformational changes affect HSA binding properties because affinity of glycated HSA for different ligands (long chain fatty acids, bilirubin, copper) undergoes an important decrease [57]. Through, these various processes, the antioxidant capacities of glycated HSA are dramatically reduced [54,58,59].

In physiological conditions, due to the large amount of HSA in plasma, impairments in the protein molecule and its antioxidant properties have been considered as biologically insignificant [31]. However, antioxidant properties of modified HSA may be related to pathological conditions, in particular in septic and cirrhotic conditions in which the decline of HSA plasma antioxidant force also is mediated by the quantitative reduction of the HSA concentration [16,20,28,60].

Specific antioxidant capacities of commercial HSA

The finding that HSA exerts a plasma antioxidant force also is important regarding its possible therapeutic effects, because it may provide the opportunity to enhance endogenous antioxidant protection in pathological conditions by HSA infusion [61]. Commercially available HSA solutions are complex products that contain not only native HSA but also various species of HSA under different redox states, as well as several minor degradation products [46,62]. Significant HSA variability has been reported between the commercial HSA solutions (Table 1). Bioprocesses and storage conditions increase heterogeneity of HSA: truncated, cysteinylated, nitrosylated, and glycosylated forms or HSA-HSA dimers may be found in commercialized products [29]. These frequently encountered modifications can change HSA antioxidant properties and its binding capacity to endogenous or exogenous molecules [29,51,63]. The observed heterogeneity also can potentially influence clinical outcome and should be correlated with morbidity/mortality in randomized trials [47,63,64]. The use of an antioxidant for the treatment of sepsis has been considered a new, interesting, adjunctive therapy and constitutes a challenge in the clinical management of these patients [17]. However, it is still unclear whether the administration of commercially available HSA that is largely oxidized, increases or decreases oxidative stress burden in critically ill patients [52].

Table 1

Characteristics of commercial HSA (available solutions for infusion in France)[29]

Human albumin baxter 200 g/l®Albunorm®Vialebex®
Manufacturer
Baxter
Octapharma
LFB
Available presentations
Newborns and infants:
20% (200 mg/ml): 10 ml vial (2 g)
Adults:
20% (200 mg/ml):
20% (200 mg/ml):
20% (200 mg/ml):
50 ml vial (10 g)
50 ml vial (10 g)
50 ml vial (10 g)
100 ml vial (20 g)
100 ml vial (20 g)
100 ml vial (20 g)
5% (50 mg/ml):
5% (50 mg/ml):
100 ml vial (5 g)
250 ml vial (12.5 g)
250 ml vial (12.5 g)
500 ml vial (25 g)
500 ml vial (25 g)
4% (40 mg/ml):
4% (40 mg/ml):
100 ml vial (4 g)
100 ml vial (4 g)
250 ml vial (10 g)
250 ml vial (10 g)
500 ml vial (20 g)
500 ml vial (20 g)
Indications (EMA)Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and the use of a colloid is appropriate. The choice of albumin rather than an artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

Until now, several analytical techniques have been employed to monitor the heterogeneity or the degradation profiles of HSA. High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and Western blot analyses, or Capillary Zone Electrophoresis (CZE) have contributed to point out this heterogeneity of commercial HSA [51,62]. Aggregation or chemical degradation can be induced during sample preparation or purification. Procedures, such as temperature variations, freeze-thawing process, mechanical agitation, or lyophilization, may affect HSA structure and composition of therapeutic HSA. Anraku et al. studied the protective effect of sodium N-acetyl-L-tryptophanate against albumin oxidation, using HPLC. They partially resolved mercaptalbumin (reduced form of HSA) from two populations of non-mercaptalbumin (oxidized forms), demonstrating that it is possible to improve the quality of the solutions [65]. Ogasawara et al. used SDS-PAGE and Western blot analyses to detect albumin disulfide dimers in plasma, considered to be a biomarker of oxidative stress [66]. More recently, Qian et al. (2008) reported a size exclusion HPLC method to estimate the proportion of HSA dimers and oligomers suitable for a quality control [67]. MS and MS coupled to HPLC also have been employed to characterize different variants of HSA in commercial HSA preparations. In particular, six related proteins have been identified but the method provided only qualitative data and did not detect any dimer form of HSA [52]. Finally, Alahmad et al. developed a reproducible CZE method to separate HSA from most of its variants. This method proved to be useful in detecting quantitative differences in the proportion of native HSA present in batches produced according to different fractionation ways [51]. Because an increased percentage of oxidized HSA is responsible for impaired HSA functions [28], the development of a reliable method providing qualitative and quantitative data on HSA variants in commercial preparations, especially the ratio of native HSA to degraded forms, is of paramount importance for optimizing the clinical use of HSA.

Implications for further studies

As we have previously mentioned, studies using HSA as a resuscitation fluid have shown conflicting results in septic and cirrhotic conditions. The relative contribution of resuscitation fluid capacity and antioxidant properties should be further investigated because it may influence the design of future trials. As a matter of fact, the rationale for infusing HSA was different in recent albumin trials which may account for different results. Should we rely on albuminemia and at what threshold: 30 g/l, or specific plasma concentrations (e.g. thiols, markers of ROS aggression)? The clinical studies have used different quantities of HSA infusion and various commercial forms of HSA. Regarding the HSA quality, it is well established that significant variability exists between the different commercial HSA solutions. They contain native HSA associated with various species of HSA in different redox states. They also contain several minor degradation products [47,63]. These modifications are known to change the antioxidant capacities of HSA and may account for the observed heterogeneity in the results of clinical trials [29,46,51,63,64]. It would be interesting to conduct an analysis correlating, for each clinical trial, the qualitative and quantitative characteristics of HSA infusion with the observed results in critically ill patients.

Moreover, the main characteristics of commercially available HSA should be tested in vitro, because they may differ from one product to another with different in vivo effect. The elucidation of the composition of commercialized HSA used in critically ill patients, with particular attention to the oxidized forms of HSA, is of great interest for the understanding of the observed variability in the results of clinical trials.

Finally, it is relevant to pursue the investigations concerning HSA antioxidant functions in physiological and pathophysiological conditions. Accumulative evidence suggests that HSA may interfere with microcirculation and endothelium function through an interaction with glycocalyx and specific antioxidant properties [68]. As a consequence, monitoring of endothelial function and microcirculation may guide HSA administration and contribute to the optimization of tissue perfusion in septic shock. The preliminary results of the Albios trial (presented orally at the ESICM meeting in Lisbon October 2012) suggest that HSA was effective in the subgroup of patients with the most severe form of sepsis which is septic shock. Future trials should probably focus on that specific high-risk population [69].

Conclusions

It is well established that, among plasma antioxidants, endogenous HSA is considered the main extracellular molecule responsible for maintaining the plasma redox state [16,29]. Its specific antioxidant functions are due to its multiple ligand-binding capacities and free radical-trapping properties and are closely related to the structure and the redox state of the molecule [16,29]. Some clinical studies have revealed positive effects or beneficial trends of HSA infusion [4,5]. Importantly, these trials have been conducted in critical pathologies in which oxidative stress plays a central detrimental role [1,15]. It seems relevant to consider that the specific antioxidant properties of the HSA molecule are involved in the positive therapeutic effects of HSA infusion, reported in the critical care and hepatological setting. In this hypothesis, using HSA as a resuscitation fluid could represent an opportunity to enhance endogenous antioxidant protection in critical pathological conditions [1,61]. Because an increased percentage of oxidized HSA is responsible for impaired HSA functions [50], we propose that preference should be given to preparations with a higher reduced HSA percentage.

Abbreviations

Cys: Cysteine; CZE: Capillary Zone Electrophoresis; GSH: Glutathione; HPLC: High-Performance Liquid Chromatography; HSA: Human Serum Albumin; ICU: Intensive Care Units; Met: Methionine; MS: Mass Spectrometry; NO: Nitric Oxide; RNS: Reactive Nitrogen Species; ROS: Reactive Oxygen Species; SDS-PAGE: Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis.

Competing interests

Pr Myriam Taverna, Anne-Lise Marie, and Pr Bertrand Guidet have received honorarium from LFB Biomedicaments and Fresenius Kabi. Pr Jean-Paul Mira has received honorarium from LFB Biomedicaments and Baxter.

Authors’ contributions

All authors contributed to the drafting of the manuscript and approved the final version.

Acknowledgements

This review article was supported by LFB Biomedicaments. The authors thank Julie Marc for editorial assistance in the preparation of the manuscript.

References

  • 1. FanaliGdi MasiATrezzaVMarinoMFasanoMAscenziPHuman serum albumin: from bench to bedsideMol Aspects Med201233209290[PubMed][Google Scholar]
  • 2. FinferSBellomoRBoyceNFrenchJMyburghJNortonRSAFE Study InvestigatorsA comparison of albumin and saline for fluid resuscitation in the intensive care unitN Engl J Med200435022472256[PubMed][Google Scholar]
  • 3. SchortgenFGirouEDeyeNBrochardLCRYCO Study GroupThe risk associated with hyperoncotic colloids in patients with shockIntensive Care Med20083421572168[PubMed][Google Scholar]
  • 4. DuboisMJOrellana-JimenezCMelotCDe BackerDBerreJLeemanMBrimioulleSAppoloniOCreteurJVincentJLAlbumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot studyCrit Care Med20063425362540[PubMed][Google Scholar]
  • 5. FinferSMcEvoySBellomoRMcArthurCMyburghJNortonRSAFE Study InvestigatorsImpact of albumin compared to saline on organ function and mortality of patients with severe sepsisIntensive Care Med2011378696[PubMed][Google Scholar]
  • 6. SortPNavasaMArroyoVAldeguerXPlanasRRuiz-del-ArbolLCastellsLVargasVSorianoGGuevaraMGinesPRodesJEffect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitisN Engl J Med1999341403409[PubMed][Google Scholar]
  • 7. TollefsonBJJonesAEDoes resuscitation with albumin-containing solutions improve mortality in sepsis?Ann Emerg Med201259432433[PubMed][Google Scholar]
  • 8. DelaneyAPDanAMcCaffreyJFinferSThe role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysisCrit Care Med201139386391[PubMed][Google Scholar]
  • 9. VincentJLNavickisRJWilkesMMMorbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trialsCrit Care Med20043220292038[PubMed][Google Scholar]
  • 10. PerelPRobertsIColloids versus crystalloids for fluid resuscitation in critically ill patientsCochrane Database Syst Rev20126CD000567[PubMed][Google Scholar]
  • 11. QuinlanGJMargarsonMPMumbySEvansTWGutteridgeJMAdministration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletionClin Sci (Lond)199895459465[PubMed][Google Scholar]
  • 12. QuinlanGJMumbySMartinGSBernardGRGutteridgeJMEvansTWAlbumin influences total plasma antioxidant capacity favorably in patients with acute lung injuryCrit Care Med200432755759[PubMed][Google Scholar]
  • 13. JainRKChakravortyNChakravortyDBhattacharyaPKYadavaAAgarwalRCAlbumin: an overview of its place in current clinical practiceIndian J Anaesth200448433438[Google Scholar]
  • 14. RostokerGGriuncelliMLoridonCBourletTIllouzEBenmaadiAModulation of oxidative stress and microinflammatory status by colloids in refractory dialytic hypotensionBMC Nephrol20111258[PubMed][Google Scholar]
  • 15. RocheMRondeauPSinghNRTarnusEBourdonEThe antioxidant properties of serum albuminFEBS Lett200858217831787[PubMed][Google Scholar]
  • 16. OettlKStauberREPhysiological and pathological changes in the redox state of human serum albumin critically influence its binding propertiesBr J Pharmacol2007151580590[PubMed][Google Scholar]
  • 17. AndradesMERitterCDal-PizzolFThe role of free radicals in sepsis developmentFront Biosci20091277287[Google Scholar]
  • 18. HuetODupicLHarroisADuranteauJOxidative stress and endothelial dysfunction during sepsisFront Biosci20111619861995[PubMed][Google Scholar]
  • 19. Ait-OufellaHMauryELehouxSGuidetBOffenstadtGThe endothelium: physiological functions and role in microcirculatory failure during severe sepsisIntensive Care Med20103612861298[PubMed][Google Scholar]
  • 20. HuetOObataRAubronCSpraul-DavitACharpentierJLaplaceCNguyen-KhoaTContiMVicautEMiraJPDuranteauJPlasma-induced endothelial oxidative stress is related to the severity of septic shockCrit Care Med200735821826[PubMed][Google Scholar]
  • 21. GalleyHFOxidative stress and mitochondrial dysfunction in sepsisBr J Anaesth20111075764[PubMed][Google Scholar]
  • 22. ParolaMRobinoGOxidative stress-related molecules and liver fibrosisJ Hepatol200135297306[PubMed][Google Scholar]
  • 23. IzzetTOsmanKEthemUNihatYRamazanKMustafaDHafizeURizaKABirsenAHabibeGSevalAGonulSOxidative stress in portal hypertension-induced rats with particular emphasis on nitric oxide and trace metalsWorld J Gastroenterol20051135703573[PubMed][Google Scholar]
  • 24. LieberCSRole of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseasesAdv Pharmacol199738601628[PubMed][Google Scholar]
  • 25. PetersTJrSerum albuminAdv Protein Chem198537161245[PubMed][Google Scholar]
  • 26. CarterDCHoJXStructure of serum albuminAdv Protein Chem199445153203[PubMed][Google Scholar]
  • 27. PetersTJAll about albumin1996San Diego: Academic
  • 28. OtagiriMChuangVTPharmaceutically important pre- and posttranslational modifications on human serum albuminBiol Pharm Bull200932527534[PubMed][Google Scholar]
  • 29. GuidetBRichard C, Teboul JL, Vincent JLAlbumin. Acute circulatory failureRéanimation2009Elsevier343356[Google Scholar]
  • 30. StohsSJBagchiDOxidative mechanisms in the toxicity of metal ionsFree Radic Biol Med199518321336[PubMed][Google Scholar]
  • 31. HalliwellBAlbumin–an important extracellular antioxidant?Biochem Pharmacol198837569571[PubMed][Google Scholar]
  • 32. YoungISWoodsideJVAntioxidants in health and diseaseJ Clin Pathol200154176186[PubMed][Google Scholar]
  • 33. JacobsenCLysine residue 240 or human serum albumin is involved in high-affinity binding of bilirubinBiochem J1978171453459[PubMed][Google Scholar]
  • 34. NeuzilJStockerRFree and albumin-bound bilirubin are efficient co-antioxidants for a-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidationJ Biol Chem19942691671216719[PubMed][Google Scholar]
  • 35. PapatheodorouLWeissNVascular oxidant stress and inflammation in hyperhomocysteinemiaAntioxid Redox Signal2007919411958[PubMed][Google Scholar]
  • 36. RubboHParthasarathySBarnesSKirkMKalyanar-amanBFreemanBANitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivativesArch Biochem Biophys19953241525[PubMed][Google Scholar]
  • 37. QuinlanGJMartinGSEvansTWAlbumin: biochemical properties and therapeutic potentialHepatology20054112111219[PubMed][Google Scholar]
  • 38. ColomboGClericiMGiustariniDRossiRMilzaniADalle-DonneIRedox albuminomics: oxidized albumin in human diseasesAntioxid Redox Signal20121715151527[PubMed][Google Scholar]
  • 39. KingTPOn the sulfhydryl group of human plasma albuminJ Biol Chem1961236PC5[PubMed][Google Scholar]
  • 40. GutteridgeJMAntioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritisBiochim Biophys Acta1986869119127[PubMed][Google Scholar]
  • 41. TurellLBottiHCarballalSFerrer-SuetaGSouzaJMDuránRFreemanBARadiRAlvarezBReactivity of sulfenic acid in human serum albuminBiochemistry200847358367[PubMed][Google Scholar]
  • 42. CarballalSRadiRKirkMCBarnesSFreemanBAAlvarezBSulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitriteBiochemistry20034299069914[PubMed][Google Scholar]
  • 43. TurellLCarballalSBottiHRadiRAlvarezBOxidation of the albumin thiol to sulfenic acid and its implications in the intravascular compartmentBraz J Med Biol Res200942305311[PubMed][Google Scholar]
  • 44. CantinAMPaquetteBRichterMLarivéePAlbumin-mediated regulation of cellular glutathione and nuclear factor kappa B activationAm J Respir Crit Care Med200016215391546[PubMed][Google Scholar]
  • 45. RafikovaORafikovRNudlerECatalysis of S-nitrosothiols formation by serum albumin: the mechanism and implication in vascular controlProc Natl Acad Sci USA20029959135918[PubMed][Google Scholar]
  • 46. BourdonELoreauNLagrostLBlacheDDifferential effects of cysteine and methionine residues in the antioxidant activity of human serum albuminFree Radic Res2005391520[PubMed][Google Scholar]
  • 47. BourdonEBlacheDThe importance of proteins in defense against oxidationAntioxid Redox Signal20013293311[PubMed][Google Scholar]
  • 48. BerlettBSStadtmanERProtein oxidation in aging, disease, and oxidative stressJ Biol Chem19972722031320316[PubMed][Google Scholar]
  • 49. HoltMERyallMECampbellAKAlbumin inhibits human polymorphonuclear leucocyte luminol-dependent chemiluminescence: evidence for oxygen radical scavengingBr J Exp Pathol198465231241[PubMed][Google Scholar]
  • 50. KawakamiAKubotaKYamadaNTagamiUTakehanaKSonakaISuzukiEHirayamaKIdentification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functionsFEBS J200627333463357[PubMed][Google Scholar]
  • 51. AlahmadYTranNTLe PotierIForestEJorieuxSTavernaMA new CZE method for profiling human serum albumin and its related forms to assess the quality of biopharmaceuticalsElectrophoresis201132292299[PubMed][Google Scholar]
  • 52. Bar-OrDBar-OrRRaelLTGardnerDKSloneDSCraunMLHeterogeneity and oxidation status of commercial human albumin preparations in clinical useCrit Care Med20053316381641[PubMed][Google Scholar]
  • 53. IwaoYAnrakuMYamasakiKKragh-HansenUKawaiKMaruyamaTOtagiriMOxidation of Arg-410 promotes the elimination of human serum albuminBiochim Biophys Acta20061764743749[PubMed][Google Scholar]
  • 54. RondeauPBourdonEThe glycation of albumin: structural and functional impactsBiochimie201193645658[PubMed][Google Scholar]
  • 55. IbergNFluckigerRNonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sitesJ Biol Chem19862611354213545[PubMed][Google Scholar]
  • 56. AhmedNDoblerDDeanMThornalleyPJPeptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activityJ Biol Chem200528057245732[PubMed][Google Scholar]
  • 57. ShaklaiNGarlickRLBunnHFNonenzymatic glycosylation of human serum albumin alters its conformation and functionJ Biol Chem198425938123817[PubMed][Google Scholar]
  • 58. RondeauPSinghNCaillensHBourdonEOxidative stresses induced by glycated human or bovine serum albumins on human monocytesFree Radic Biol Med200845799812[PubMed][Google Scholar]
  • 59. SakataNMohATakebayashiSContribution of superoxide to reduced antioxidant activity of glycoxidative serum albuminHeart Vessels2002172229[PubMed][Google Scholar]
  • 60. Bar-OrDRaelLTBar-OrRSloneDSCraunMLThe formation and rapid clearance of a truncated albumin species in a critically ill patientClin Chim Acta2006365346349[PubMed][Google Scholar]
  • 61. EvansTWReview article: albumin as a drug–biological effects of albumin unrelated to oncotic pressureAliment Pharmacol Ther200216Suppl 5611[PubMed][Google Scholar]
  • 62. FlanBQuality control of human albumin solutionsAnn Fr Anesth Reanim199615547552[PubMed][Google Scholar]
  • 63. OtagiriMKragh-HansenUImaiTAlbumins with new functions and clinical applicationsDrug Metab Pharmacokinet200924285286[PubMed][Google Scholar]
  • 64. Bar-OrDThomasGWBar-OrRRaelLTScarboroughKRaoNShimonkevitzRCommercial human albumin preparations for clinical use are immunosuppressive in vitroCrit Care Med20063417071712[PubMed][Google Scholar]
  • 65. AnrakuMKounoYKaiTTsurusakiYYamasakiKOtagiriMThe role of N-acetyl-methioninate as a new stabilizer for albumin productsInt J Pharm20073291924[PubMed][Google Scholar]
  • 66. OgasawaraYNamaiTTogawaTIshiiKFormation of albumin dimers induced by exposure to peroxides in human plasma: a possible biomarker for oxidative stressBiochem Biophys Res Commun2006340353358[PubMed][Google Scholar]
  • 67. QianJTangQCroninBMarkovichRRustumADevelopment of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2bJ Chromatogr A200811944856[PubMed][Google Scholar]
  • 68. KremerHBaron-MenguyCTesseAGalloisYMercatAHenrionDAndriantsitohainaRAsfarPMezianiFHuman serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent propertiesCrit Care Med20113914141422[PubMed][Google Scholar]
  • 69. GattinoniLAlbumin in Severe Sepsis and Septic Shock: the ALBIOS Study2012Lisbon: ESICM Lives 2012 Lisbon, 25th annual congress20113-17 October 2012. Session fluid therapy in septic shock
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.